Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US
Author:
Publisher
Informa UK Limited
Subject
Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.3109/0284186X.2012.707784
Reference14 articles.
1. Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia
2. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
3. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
4. Cancer Survival and Incidence from the Surveillance, Epidemiology, and End Results (SEER) Program
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinical profile of FTL3-ITD mutation in West Algerian population with acute myeloid leukemia;MOL BIOL RES COMMUN;2024
2. Disparity in hematological malignancies: From patients to health care professionals;Blood Reviews;2024-05
3. Informed consent for genetic testing in hematology;Hematology;2020-12-04
4. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map;Blood Reviews;2020-07
5. Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989–2017;Leukemia;2020-06-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3